TIC JOURNAL

SECOND SEMESTER 2024/2025




TABLE OF CONTENTS

Asset Management

Bridging Engineering and Finance:
A Semester of Risk Innovation at TIC
By Tiago Antunes

p. 3

Investment Banking

Deal by Deal: How M&A Is Rewriting the U.S. Health System By Maria do Mar Vieira & Francisco Falcão

p. 4

Lantheus in 2025: Chasing Growth, Facing Doubt By Carolina Nunes

p. 6

Quantitative Trading

From ideas to reality - our road to Strategy Application


p. 7

By João Pedro Afonso & Tomás Juhos

TIC JOURNAL, SECOND SEMESTER 2024/2025

Asset Management TIC

BRIDGING ENGINEERING AND FINANCE: A SEMESTER OF RISK INNOVATION AT TIC



By Tiago Antunes

Reading the Rapids Before We Leap

Imagine hikers facing a fast-moving river. One route hops from rock to rock, the other wades straight through. Knowing each stone's slipperiness and every ford's depth turns a gamble into a decision.

this semester, TIC's Asset Management team relied almost entirely macroeconomic forecasts, our "weather report", to guide portfolio choices. We saw gathering clouds but couldn't measure how slick each step might be. To close that gap, we split into Macro (scanning the skies) and Risk (testing the stones). This article reflects on what the newly formed Risk team built, why it matters, and how it shifted our culture.

the Compass From **Spreadsheet Chaos to Structured Code**

A reliable compass must work in any conditions. For us, that meant replacing ad-hoc spreadsheets with an objectoriented Python framework that answers three questions in real time:

- 1. What do we own?
- 2. How much cash do we have?
- 3. If a position tanks overnight, how bad could it get?

Out of this sprang three core classes:

Stock: Wraps Yahoo Finance: fetches price history, computes daily returns, and outputs Sharpe, Sortino, beta, and other ratios.

Portfolio: Marks positions to market, tracks residual cash, aggregates to portfolio-level metrics, and runs Monte Carlo simulations

to stress-test thousands of scenarios.

Transactions: Replays every buy and sell, day by day, reconciling cash balances and offering an Excel importer so non-coders can log trades seamlessly.

Together, these modules form a plug-andplay engine. Any member can fork the repo, point it at their transaction file, and instantly regenerate TIC's risk picture on their own laptop.

Automation: Risk That Updates While We Sleep

Early on, checking risk felt like lifting a bucket lid every few hours. Now, our scripts act as sensors:

- Each morning a scheduled job pulls the latest market data.
- Metrics get recomputed and stored as tidy CSVs.
- A monitor scans for breached stop-loss or take-profit thresholds and autogenerates sell orders before breakfast.

By shifting from manual polling to automated updating, the Risk team spends meetings interpreting signals instead of gathering them, because risk unfolds on market time, not meeting time.

Turning Data Into Stories

Numbers convince analysts; visuals convince everyone else. Once our backend was stable, we focused on storytelling in Power BI. Dashboards now members instantly:

of total value, drawdowns, and Monte current, we turn blind jumps into Carlo price paths.

Stock Analysis: Interactive tabs for each holding, showing price history alongside marginal risk contributions.

Advanced Risk Metrics: Heat maps of Sharpe, Sortino, and volatility impacts, with color flags for outliers.

Asset Allocation & Exposure: Donut charts and treemaps by sector, region, and side-by-side market and a performance versus ETF benchmarks.

Thanks to automatic CSV refreshes, what used to take a lifetime now takes one click. When Macro proposes a new

position, Risk can instantly visualize its effect on drawdown or VaR. Dialogue replaces guesswork.

A Culture of Continuous Improvement

Engineering students love to tinker. We designed our platform to invite contributions: new risk metrics can be added via pull requests; custom visualizations drop straight into Power BI by dumping a CSV.; documentation with clear docstrings and pervasive type hints lowers the barrier for newcomers. This volunteer-driven club depends on handovers each semester. By embedding good engineering practices, we ensure each cohort builds on the last, creating a virtuous cycle where today's beginners become tomorrow's maintainers.

Looking Back to Look Forward


Splitting Asset Management into Macro and Risk wasn't about creating silos-it was about sharpening focus. The Macro team surveys global interest-rate trends, geopolitical shifts, and sector rotations. The Risk team operates the microscope, checking that every decision aligns with our risk appetite. When these perspectives converge, we make choices that balance vision with terrain. Every enhancement brings us closer to a self-aware portfolio. Next steps include: expanding metrics conditional VaR, drawdown attribution); integrating alternative data for stress-scenarios; onboarding scripts to help new members spin up the environment in minutes.

greet Crossing Rivers With Eyes Open


Uncertainty is inevitable, rivers will Portfolio Overview: A "heartbeat" chart always flow. But by measuring depth and calculated strides. This semester, TIC's Risk team built: a **reusable codebase** that codifies every position and trade; automated sensors that update metrics overnight; interactive dashboards that translate data into actionable stories; a culture that rewards curiosity, documentation, and continuous refinement.

> This milestone is just the beginning. As future cohorts encounter new currents, they'll have both a sturdy compass and the habit of checking it. We'll keep listening to the data, learning from surprises, and improving our framework as engineers, as investors, and as a community united by thoughtful risk-taking.

DEAL BY DEAL: HOW M&A IS REWRITING THE U.S HEALTH SYSTEM



By Maria do Mar Vieira



By Francisco Falcão

Mergers and acquisitions are reshaping the U.S. healthcare landscape. From national hospital systems downsizing, to regional providers and academic medical centers expanding their reach, the new dynamics raise pressing questions: will patients gain better access and care, or will consolidation reduce affordability and competition?

As strategic and financial pressures collide, stakeholders must reassess what healthcare delivery will look like in 2025 and beyond.

Unlike many European nations with funded centralized, publicly systems, the U.S. healthcare system is a complex mix of public and private providers, insurers, investors. and Hospitals operate under diverse ownership models (nonprofit, for-profit, academic, religious) and rely heavily on reimbursements from private insurers and government programs like Medicare and Medicaid.

This fragmented landscape makes the system highly susceptible to economic pressures and policy shifts, making mergers and acquisitions a powerful tool for strategic repositioning.

A Post-COVID Financial Emergency

Since the COVID-19 pandemic, many U.S. hospital systems have experienced a perfect storm of financial distress. Declining revenues, staff shortages, and rising wage demands have destabilized operations. Besides, the potential for cuts in Medicaid reimbursements, due to Congressional budget negotiations, has made the outlook more precarious.

In response, large national systems are underperforming assets. For instance, significantly reduced its Ascension presence in Michigan by selling several hospitals to regional players like Beacon MyMichigan and Health. CommonSpirit Health also exited San Francisco, selling two hospitals to UCSF

These divestitures aim to sharpen focus on core markets and preserve profitability. However, for patients, they raise concerns about service continuity, especially in vulnerable regions.

For investors, they represent both opportunity and risk: acquiring facilities at a discount while navigating potential regulatory and operational challenges.

The Regional Growth Strategy

While national players pull back, many regional systems are doubling down. By acquiring divested hospitals, providers are scaling their networks and strengthening geographic footprints. Florida-based BayCare Health, example, ended a joint venture to assume full operational control and secured \$1.3 billion in funding.

Similarly, Orlando Health expanded aggressively in 2024, purchasing hospitals across Florida and Alabama. These moves, backed by nearly \$2 billion in bridge loans and long-term financing, signal confidence in the benefits of regional consolidation.

This strategy could translate into more consistent service quality and improved care integration. But it also introduces risks: less competition in certain areas may lead to higher costs, and integration failures could disrupt patient care. For investors, understanding these dynamics is key to evaluating long-term value creation.


This chart illustrates the evolution of healthcare bond issuance in the U.S. from 2015 to 2024. After years of fluctuations, affected by macroeconomic uncertainty. regulatory shifts, and COVID-19 pressures, issuance reached a low point in 2023, with just \$17.7 billion.

In 2024, however, issuance rebounded sharply to \$35.6 billion, more than doubling year-over-year. This surge was driven by renewed expansion strategies streamlining operations by divesting among regional systems and academic medical centers, which leveraged debt markets to fund hospital acquisitions, infrastructure upgrades, and clinical network development.

> The breakdown includes tax-exempt municipal bonds—both fixed and variable rate—as well as taxable corporate debt, reflecting different financing strategies and risk profiles. For investors, this rebound indicates growing confidence in the sector's long-term viability, despite ongoing operational risks and regulatory challenges. The financing boom is a central enabler of current M&A dynamics in U.S. healthcare.

T I C ______ Investment Banking

Figure 1: Healthcare Issuance More Than Doubled in 2024 (\$s in Billions)



Source: Refinitiv, Bond Buyer

Academic Medical Centers on the Rise

Academic medical centers (AMCs) are increasingly becoming key players in the healthcare M&A landscape. These institutions are strategically acquiring community hospitals to relieve overcrowding at their main campuses while expanding care accessibility across broader geographies.

For example, in 2025, UMass Memorial acquired Milford Regional Medical Center using proceeds from a \$342 million bond issuance. Likewise, the University of Maryland Medical System secured over \$500 million in financing to build a new medical facility serving Maryland's eastern shore. These expansions are not just about infrastructure, they are about shifting car models.

By offloading low-acuity care to satellite hospitals, AMCs are reserving their core facilities for high-complexity treatments and research, creating a more efficient and specialized system. However, this shift comes with challenges, including maintaining quality standards across diverse sites and managing the high costs of expansion.

Risks and Rewards for Investors and Patients

The wave of M&A activity across the U.S. healthcare sector presents a double-edged sword. For investors, it opens up new avenues for strategic positioning whether through acquisition of undervalued assets, partnerships with expanding systems, or financing major transitions.

Yet it also demands caution: integration risks, regulatory scrutiny, and potential political backlash could all affect valuations and returns.

Patients stand at the heart of this transformation. In ideal scenarios, consolidation leads to streamlined operations, expanded service offerings, and better outcomes. But if mergers reduce competition or result in closures, communities may face fewer options and higher costs.


As 2025 unfolds, healthcare M&A will continue to redefine the delivery of care in the United States. Stakeholders must weigh efficiency against equity, growth against access and, ultimately, financial strategy against human impact.

TIC JOURNAL, SECOND SEMESTER 2024/2025

Investment Banking

TIC

LANTHEUS IN 2025: CHASING GROWTH, FACING DOUBT



By Carolina Nunes

In recent years, Lantheus Holdings has undergone a remarkable transformation from a mid-sized, relatively unknown radiopharmaceutical company into a prominent player in diagnostic imaging. Headquartered in Massachusetts, the company has seen significant revenue growth, primarily driven by the success of its flagship product, Pylarify. However, despite these achievements, investor confidence has remained cautious. The company's share price has shown notable volatility, and recent performance updates have only added to the uncertainty. As Lantheus embarks on a new phase characterised by acquisitions and pipeline expansion, the central question becomes whether its current strategy will sustain long-term growth.

Sector and Company Overview

Radiopharmaceuticals are playing a growing role in medical imaging, driven by better diagnostic accuracy and the move toward personalised care. Despite strong potential, the sector is complex—high costs, rigid regulations, and short product shelf-life present ongoing challenges.

In this context, Lantheus, established in 1956, is positioned within this complex landscape as a specialist in oncology and cardiology imaging solutions. Additionally, the company has also pursued strategic partnerships to support innovation and product development, reinforcing its focus on precision medicine. Although its sales operations are currently confined to the U.S. market, Lantheus extends its reach through licensing agreements with international distributors.

Lantheus' portfolio is dominated by two key products: Pylarify, a PET imaging agent for recurrent prostate cancer that accounts for over 65% of revenue, and Definity, with more than 20%. While the company also markets several other diagnostic agents, their impact is more limited. Lantheus competes in a crowded field, facing companies such as Telix Pharmaceuticals, Bracco's Blue Earth Diagnostics, and GE Healthcare.

The Pylarify Breakthrough and Its Impact

As recently as 2019, Lantheus generated approximately \$350 million in annual revenue, with Definity as its primary contributor. The company's trajectory shifted significantly in 2020driven by better diagnostic accuracy and the move toward personalised care. Despite strong potential, the sector is complex—high costs, rigid regulations, and short product shelf-life present ongoing challenges.

In this context, Lantheus, established in 1956, is positioned within this complex landscape as a specialist in oncology and cardiology imaging solutions. Additionally, the company has also pursued strategic partnerships to support innovation and product development, reinforcing focus precision its on medicine. Although its sales operations are currently confined to the U.S. market, Lantheus extends its reach through licensing agreements with international distributors.

Lantheus' portfolio is dominated by two key products: Pylarify, a PET imaging agent for recurrent prostate cancer that accounts for over 65% of revenue, and Definity, with more than 20%. While the company also markets several other diagnostic agents, their impact is more limited. Lantheus competes in a crowded field, facing companies such as Telix Pharmaceuticals, Bracco's Blue Earth Diagnostics, and GE Healthcare.

The Pylarify Breakthrough and Its initiating legal action to challenge the Impact patents—an increasingly common path in

As recently as 2019, Lantheus generated approximately \$350 million in annual revenue, with Definity as its primary contributor. The company's trajectory shifted significantly in 2020 with the acquisition of Progenics, setting the stage for the launch of Pylarify in 2021. This new product catalysed a phase of rapid expansion, pushing revenues beyond the \$1 billion mark and delivering triple-digit year-over-year growth at its peak.

Pylarify's success stemmed from its **PSMA-targeting** mechanism. which enabled precise detection of recurrent prostate cancer. Its clinical combined with CMS reimbursement approval, led to rapid adoption and significant revenue acceleration. As the product gained traction, it became the backbone of Lantheus' commercial strategy —allowing the company to reinvest in its pipeline and consider expansion into adjacent fields.

A Sudden Shift in 2025

The narrative changed in 2025. In Q1 2025, Pylarify sales had a 0.5% decline and overall revenue remained flat. Following the results, the management also announced a guidance downgrade, triggering a 23% drop in the share price. While management cited pricing and reimbursement pressures, their emphasis on acquisitions and future strategy left investors with limited clarity on near-term performance.

The Uncertain Path Ahead


During 2025, Lantheus completed two strategic acquisitions: Evergreen Theragnostics and Molecular Life Imaging. These moves aim to strengthen the company's position in oncology and broaden its footprint into Alzheimer's diagnostics. These acquisitions added manufacturing capabilities and a new Alzheimer's pipeline, including MK-6240, expected to file for NDA in 2025. While they broaden Lantheus' market potential, their success depends on regulatory progress and effective integration. The expiry of Pylarify's exclusivity on May 25, 2025, introduces another layer of complexity. While patent protections remain valid through 2037, generic competitors can now file for approval. Their options include waiting expiration, negotiating a license, or patents—an increasingly common path in this sector. Lantheus also depends on third-party manufacturers for components, which could affect production if disruptions occur.

Lantheus showed strong growth with Pylarify's success, but momentum is slowing. With key assets nearing regulatory review and acquisitions being integrated, the second half of 2025 will be pivotal. Future performance hinges on scientific results and the company's ability to manage rising operational challenges.


TIC JOURNAL, SECOND SEMESTER 2024/2025

Quantitative Trading TIC

FROM IDEAS TO REALITY - OUR ROAD TO STRATEGY APPLICATION



By João Pedro Afonso



By Tomás Juhos

Throughout the years of work at the Quantitative Trading Department, we have studied and developed several methods to create systematic algorithmic strategies, either based on Portfolio Optimization techniques or Machine Learning methods. It was a period of great growth and learning, but every time we shared our excitement and progress, people would always ask the same questions: So, how did it go? Did you get it up and running? Did it work? And most importantly... Is it making

These questions were the motivation to create a new team: the Strategy **Application** team. During the past semester, this team developed the missing piece our department needed: a structured pipeline that enables our teams to turn their ideas into real, live investment strategies - up and running, delivering results (and yes, making money! Although only paper trading for now).

The Structure

This automated process is built around four main stages: Data ETL, Signal **Generation**, Order Orchestration,

and Monitoring and Publishing the Based on this classification, for Meanresults on our Website. The whole pipeline is Python-based, leveraging **Postgres** data storage for management. Currently our strategies are deployed on Alpaca's paper trading accounts, which should provide a very close proxy to real trading, by charging real transaction fees and exposing the strategies to slippage just like in real markets.

Extract-Transform-Load (ETL) projects. These projects connect to brokers, such as Alpaca and Binance, and keep our database up to speed with the most recent market data to allow our strategies to make decisions on freshest data.

The second main component is the Strategy Execution Pipeline. Each strategy has one instance of three microservices: signal generation, order orchestration and monitoring. Signal generation is the component where the strategy application team collaborates with other teams (Portfolio Optimization and Machine Learning) to adapt and integrate their code into a production environment turning these strategies from static to live. The order orchestration component fetches fresh signals as soon as they are produced and connects with the broker to manage positions accordingly. monitoring Lastly, have the component, a crucial step in storing the performance and positions of our strategies to allow further analysis and to expose the historic results that would be lost otherwise. To achieve this, it takes periodic snapshots of the state of the portfolio and positions in the brokerage account and stores them in our database.

The third main component is our website, and allows us to expose to the world our strategy's performance. It was developed in collaboration with the Marketing Department, which built the front-end that displays key metrics and the evolution of our strategy.

The Strategy

In order to test and to debut this structure, we have deployed our first strategy: **PO** Hurst - Crypto. This is a Long-Only strategy that uses the Hurst Exponent to Cryptocurrencies behavioral regimes: Mean-Reverting and Trending.

Reverting assets, the RSI indicator is used to generate buy signals, while the MACD is the foundation for the signals in Trending assets. These signals are generated daily using close prices, and target portfolio weights are assigned uniformly among the assets with buy signals.

Furthermore. have developed avoid mechanisms unnecessary to The first main component is the **Data** turnover and minimize transaction costs. Before each rebalance, the strategy computes the Normalized Euclidean Distance between the current portfolio weights and the new target weights. If this distance falls within a predefined notrade zone, determined by an optimal threshold δ , the strategy retains the weights thereby current avoiding unnecessary turnover. When rebalancing is triggered, it is executed through a weighted average between the current and target weights, allowing for gradual adjustments rather than full reallocation. As a result, the strategy never performs a complete portfolio turnover, effectively reducing both transaction costs and slippage over time.

> This strategy was deployed on May 6th, and its performance has been publicly trackable on our website ever since. And unsurprisingly - it's been doing quite well! While it's important to take into account that our entry was quite exceptional due to the market conditions at the time, our strategy consistently has delivered positive cumulative returns from almost day one, currently standing at around 20%.

The Future

With the pipeline built, we are now equipped with a tool that enables us to easily create and integrate different which picks up on the monitoring results strategies and track their live performances. More specifically, until the end of the semester we plan to deploy the first Machine Learning based Strategy that will trade Bitcoin, as well as a new Portfolio Optimization Strategy that also uses the Hurst Exponent, but this time rather applied to equity than cryptocurrency.

> We close the semester with a strong sense of accomplishment and pride, not only in finally showcasing the success and the quality of the work that we have been quietly developing over the last years, but also in leaving behind a tool for TIC that will allow them to keep thriving.

A Letter from the President and Vice-President

Dear TIC Members and IST Community,

As we bring another academic year to a close, we want to take a moment to thank each and every one of you for your dedication, hard work, support, and belief in what we're building together.

2024/25 was an exciting and fulfilling chapter for the Técnico Investment Club. From workshops and visits with industry professionals to participating and winning competitions. This year reminded us of the value of curiosity, collaboration and consistency. It has been a privilege to grow alongside such motivated and engaged community.

We'd like to extend special thanks to our department heads: Carolina Albuquerque (Human Capital), Inês Perry (Marketing), João Afonso (Quantitative Trading), João Filipe (Asset Management), and Tiago Portugal (Investment Banking). Your outstanding leadership and teamwork helped steer this ship forward and left a meaningful mark on your departments and the members within them.

We're also proud to share a major milestone: our live strategy tracking is now available on our website. This project reflects the way we think — thoughtful, analytical, and grounded in turning knowledge into real-world insight. It represents another step toward bridging the gap not only between theory and practice, but also between engineering and finance.

Now entering our third year since founding in 2021/22, we're beginning to see more and more alumni pursue careers at leading firms and top business schools across Europe. Their continued connection to TIC and how they carry its lessons forward makes us incredibly proud. It reminds us of the purpose behind this club and why we're committed to building something meaningful for those who follow.

To everyone who contributed this year — whether by leading an initiative, joining an event, challenging ideas, or quietly supporting in the background — thank you. Your involvement made a real difference.

There is more to come, and we can't wait to share the next chapter with you.

Wishing you a well-deserved break and continued success,

Best Regards,

João Le Coroller, President

João Filipe, Vice President

